Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.

Rong FanHatice SatilmisNiels VandewalleEmma VerheyePhilip VlummensAnke MaesCatharina MuylaertElke De BruyneEline MenuHolly EvansAndrew ChantryNathan De BeuleDirk HoseMarie TörngrenHelena ErikssonKarin VanderkerkenKen MaesKarine BreckpotKim De Veirman

Published in: Journal for immunotherapy of cancer (2023)

Our study provides novel insights in the dual therapeutic effects of the immunomodulator tasquinimod and fosters its evaluation in combination therapy trials for MM patients.

Keyphrases

combination therapy
end stage renal disease
multiple myeloma
signaling pathway
induced apoptosis
ejection fraction
chronic kidney disease
newly diagnosed
poor prognosis
peritoneal dialysis
prognostic factors
bone mineral density
acute myeloid leukemia
bone loss
immune response
soft tissue
pi k akt